A Phase II Study of IMMU 130 (hMN-14-SN38 Antibody Drug Conjugate) in Patients With Metastatic Colorectal Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Labetuzumab govitecan (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 03 Dec 2020 Planned initiation date changed from 1 Mar 2014 to 1 Sep 2013.
- 03 Dec 2020 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 18 Jan 2017 Results published in an Immunomedics media release.